KYNTRA BIO, INC.
No SEC Form 4 filings for $KYNB in the last 30 days.
See all $KYNB insider activity →KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 kynb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update • Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-re
KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0000921299 false 0000921299 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12,
Kyntra Bio, Inc. (NASDAQ:KYNB) published its Q1 2026 earnings call presentation on May 11, 2026. This slide deck accompanies the company's first-quarter financial results. The article was written by SA Transcripts, a team dedicated to publishing earnings call materials.
Over the past 7 days, alphai's AI scored 1 news story mentioning KYNB (KYNTRA BIO, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent KYNB coverage spans earnings, corporate actions and financial news.
Near-term catalyst is the company’s stated 4Q 2026 interim readout timing plus finalized roxadustat Phase 3 protocol for 4Q 2026 initiation.
Routine annual-meeting outcomes; modest governance signal but no new operating/financial catalyst.
The Q1 2026 earnings call presentation indicates steady financial performance with potential growth opportunities. Market sentiment remains neutral, reflecting investor caution amid upcoming product launches.
alphai scores every news story that mentions KYNB with an AI model for sentiment and relevance, and aggregates insider trades from KYNTRA BIO, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 kynb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update • Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-re
6 min readKYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0000921299 false 0000921299 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12,
2 min readKyntra Bio, Inc. (NASDAQ:KYNB) published its Q1 2026 earnings call presentation on May 11, 2026. This slide deck accompanies the company's first-quarter financial results. The article was written by SA Transcripts, a team dedicated to publishing earnings call materials.
3 min read
